Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers

European Radiology

Volumn 19, Issue 1, 2009, Pages 121-131

  Cyran, Clemens C ^a   Sennino, Barbara ^b   Chaopathomkul, Bundit ^a   Fu, Yanjun ^a   Rogut, Victor S ^a   Shames, David M ^a   Wendland, Michael F ^a   McDonald, Donald M ^c   Brasch, Robert C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Endothelial permeability; Experimental human breast cancer; Immunofluorescent microscopy; Macromolecular contrast agent enhanced MRI; Thalidomide

Indexed keywords

GADOLINIUM PENTETATE ALBUMIN; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTRAST ENHANCEMENT; CONTRAST MEDIUM EXTRAVASATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SENSITIVITY AND SPECIFICITY; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; MAGNETIC RESONANCE IMAGING; PROGNOSIS; RATS; RATS, NUDE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 59249100467     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-008-1111-x     Document Type: Article

References (37)

1. Mellin GW, Katzenstein M (1962) The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 267:1184-1192
2. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91(9):4082-4085
3. Bolke E, Gripp S, Peiper M, Budach W, Schwarz A, Orth K, Reinecke P, van de Nes JA (2006) Multifocal epithelioid hemangioendothelioma: Case report of a clinical chamaeleon. Eur J Med Res 11(11):462-466
4. Klausner JD, Freedman VH, Kaplan G (1996) Thalidomide as an anti-TNF-alpha inhibitor: Implications for clinical use. Clin Immunol Immunopathol 81(3):219-223
5. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177(6):1675-1680
6. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173(3):699-703
7. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK et al (2001) A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7(7):1888-1893
8. Ng SS, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD (2003) Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 63(12):3189-3194
9. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR (2000) Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 75(9):897-901
10. Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, Abbruzzese JL, Brown TD (2005) Thalidomide in the treatment of patients with hepatocellular carcinoma: A phase II trial. Cancer 103(4):749-755
11. Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E, Zhang Y, Liu Y, Li QQ (2003) Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 23(3B):2481-2487
12. Kenyon BM, Browne F, D'Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64(6):971-978
13. Zhao D, Jiang L, Hahn EW, Mason RP (2005) Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology. Neoplasia 7(7):678-687
14. Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, Roberts TP (2004) Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 20(1):138-144
15. Fournier LS, Novikov V, Lucidi V, Fu Y, Miller T, Floyd E, Shames DM, Brasch RC (2007) MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. Radiology 243(1):105-111
16. Turetschek K, Preda A, Floyd E, Shames DM, Novikov V, Roberts TP, Wood JM, Fu Y, Carter WO, Brasch RC (2003) MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. Eur J Nucl Med Mol Imaging 30(3):448-455
17. van Dijke CF, Mann JS, Rosenau W, Wendland MF, Roberts TP, Roberts HC, Demsar F, Brasch RC (2002) Comparison of MR contrast-enhancing properties of albumin-(biotin)10-(gadopentetate)25, a macromolecular MR blood pool contrast agent, and its microscopic distribution. Acad Radiol 9(Suppl 1):S257-S260
18. Schwickert HC, Roberts TP, Shames DM, van Dijke CF, Disston A, Muhler A, Mann JS, Brasch RC (1995) Quantification of liver blood volume: comparison of ultra short TI inversion recovery echo planar imaging (ULSTIR-EPI), with dynamic 3D-gradient recalled echo imaging. Magn Reson Med 34(6):845-852
19. Preda A, Turetschek K, Daldrup H, Floyd E, Novikov V, Shames DM, Roberts TP, Carter WO, Brasch RC (2005) The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors. Invest Radiol 40(6):349-354
20. Roberts TP, Brasch RC, Schwickert HC, Shames DM, vanDijke CF, Stiskal M, Mann JS, Muhler A, Demsar F (1996) Quantification of tissue gadolinium concentration using magnetic resonance imaging: Comparison of ultrashort inversion time inversion recovery echoplanar and dynamic three-dimensional spoiled gradient-recalled approaches with in vitro measurements. Acad Radiol 3(Suppl 2):S282-S285
21. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, Brasch RC (1998) Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media. Pediatr Radiol 28(2):67-78
22. Daldrup HE, Shames DM, Husseini W, Wendland MF, Okuhata Y, Brasch RC (1998) Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magn Reson Med 40(4):537-543
23. Foster DM, Boston RC, Jacquez JA, Zech L (1989) A resource facility for kinetic analysis: Modeling using the SAAM computer programs. Health Phys 57(Suppl 1):457-466
24. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD et al (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165(1):35-52
25. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156(4):1363-1380
26. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7(9):987-989
27. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J et al (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98(2):492-494
28. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM et al (2000) Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18(13):2593-2602
29. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM et al (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18(4):708-715
30. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA (2000) Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 23(3):319-321
31. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME (2000) Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82(4):812-817
32. Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, Mak I, Sapunar F, Ahern R, Gore ME (2001) The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 85(7):953-958
33. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276(25):22382-22387
34. Invernizzi R, Travaglino E, De Amici M, Brugnatelli S, Ramajoli I, Rovati B, Benatti C, Ascari E (2005) Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. Leuk Res 29(6):641-647
35. Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T (2005) Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106(1):125-134
36. Daruwalla J, Nikfarjam M, Malcontenti-Wilson C, Muralidharan V, Christophi C (2005) Effect of thalidomide on colorectal cancer liver metastases in CBA mice. J Surg Oncol 91(2):134-140
37. Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N, Cohen RL, Brasch RC (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16(4):225-230